Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib with Temozolomide and Radiotherapy in Glioblastoma
NCT02270034Phase 1Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Aug 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crizotinib in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: Treatment safety at 7 months. Started Aug 2014; status: completed.
02
Drugs
crizotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02270034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270034.